| Value | ₹0.34 Cr |
|---|
BSE filing, NSE: SARDAPPR. Summary written from the filing by ALFA Finder's alert engine.
Tahmar Enterprises Ltd: key numbers
- Share price
- ₹3.92
- Market cap
- ₹61.07 Cr
- Revenue (annual)
- ₹2.59 Cr
- Net profit (annual)
- ₹-5.60 Cr
- P/E (TTM)
- -14.4×Sector 26.8×
- Promoter holding
- 65.86%+0.00% QoQ
- FII holding
- 0.03%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Tahmar Enterprises Ltd
All →Tahmar Enterprises Other Announcement
This quarterly shareholding pattern filing provides the shareholding distribution between promoters and public shareholders for the period ending September 30, 2026, as per SEBI regulations.
Tahmar Enterprises Management Change
Ms. Kanika Kabra has resigned as an Independent Director of Tahmar Enterprises Ltd, effective October 16, 2026, due to other professional commitments.
Tahmar Enterprises Other Announcement
Tahmar Enterprises Limited filed the quarterly compliance certificate under Regulation 74(5) of SEBI (DP) Regulations, 2018, as received from its RTA, MUFG Intime India Private Limited.
Tahmar Enterprises Annual General Meeting
Tahmar Enterprises Ltd held its 35th Annual General Meeting on September 29, 2026. Shareholders adopted the annual financial statements and approved the proposed related party transactions.
Tahmar Enterprises Product Launch
Tahmar Enterprises approved entering the manufacture of Indian Made Foreign Liquor and Maharashtra Made Liquor at its existing distillery, with brand registration steps to follow.
Tahmar Enterprises Price Movement Clarification
Tahmar Enterprises replied to BSE's price-movement query, confirming no undisclosed information exists. The company stated the share price movement is purely market-driven.
Other regulatory approval announcements
All →Shalby Regulatory Approval
Shalby Hospital, Jabalpur received CMHO permission to resume normal operations, including patient admissions, on its previously affected floor. The hospital has now fully resumed healthcare services.
Elantas Beck India Regulatory Approval
Elantas Beck India's GPCB permanently revoked the closure direction on its Ankleshwar plant. The facility can keep operating, subject to compliance conditions.
Kalyani Cast-Tech Regulatory Approval
Kalyani Cast-Tech received RDSO Stage-I concept design approval for its new container-carrying wagon under PWDA. Stage-II detailed design approval is still required, subject to dynamics simulation conditions.
Mukka Proteins Regulatory Approval
Mukka Proteins received a US FDA facility registration certificate, valid October 1, 2026 to December 31, 2027. The company says the registration supports its engagement with US customers and markets.
- Execution
- October 1, 2026 to December 31, 2027
Canara Bank Regulatory Approval
Canara Bank received RBI permission to exercise the call option on its Basel III AT1 bonds (ISIN INE476A08134) of Rs.1,500 Crore. The bank is now in process of exercising the call as per the issue terms.
- Value
- ₹1,500 Cr
Alembic Pharmaceuticals Regulatory Approval
Alembic Pharmaceuticals received USFDA final approval for Valganciclovir for Oral Solution, 50 mg/mL. This adds to its cumulative 247 USFDA ANDA approvals.